Lv7
5000 积分 2022-08-11 加入
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
1个月前
已完结
Fifty years of monoclonals: the past, present and future of antibody therapeutics
3个月前
已完结
Clinical Translation of Targeted Protein Degraders
4个月前
已完结
Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider
4个月前
已完结
What Is the Potential Relevance of Growth and Differentiation Factor-15 in Neurologic Disease?
6个月前
已完结
The state of the art in secondary pharmacology and its impact on the safety of new medicines
6个月前
已完结
Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys
7个月前
已完结
Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial
7个月前
已完结
Strategies to reduce the use of non-human primates in development of oncology ADCs with cytotoxic payloads
8个月前
已完结
Navigating the complexities of drug development for inflammatory bowel disease
8个月前
已完结
皖公网安备34019202002308
